PolyPeptide Group AG is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the development and production of synthetic peptides and oligonucleotides. The company operates six cGMP-certified manufacturing facilities located in Switzerland, France, Belgium, Sweden, the United States, and India. Its core business involves partnering with pharmaceutical and biotechnology companies to manufacture active pharmaceutical ingredients (APIs) for novel drug therapies, particularly in the fast-growing area of metabolic diseases such as GLP-1 treatments. PolyPeptide offers a comprehensive suite of services spanning the entire drug lifecycle, from pre-clinical development and clinical trial supply to large-scale commercial manufacturing. In addition to custom API development, the company produces generic peptides and peptides used in cosmetics, animal health, and medical devices. By focusing exclusively on outsourced manufacturing and development rather than proprietary drug discovery, PolyPeptide positions itself as a critical supply chain partner for the global life sciences industry.
